Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DTX301 in Late-onset OTC Deficiency
NCT05345171Phase 3Active, not recruiting
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Oct 2022
- Primary completion
- Sep 2027
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 10
01
Overview
A Phase 3 trial of avalotcagene ontaparvovec in ornithine transcarbamylase deficiency, sponsored by Ultragenyx Pharmaceutical Inc.. Started Oct 2022; status: active, not recruiting.
02
Drugs
avalotcagene ontaparvovec
03
Conditions
ornithine transcarbamylase deficiency
Beyond the preview
Go deeper on NCT05345171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05345171.